Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation

Chest

Volumn 147, Issue 3, 2015, Pages e79-e82

  Yousef, Shatha ^a   Solomon, George M ^b   Brody, Alan ^c   Rowe, Steven M ^b   Colin, Andrew A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b and Clinical Center   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DORNASE ALFA; IVACAFTOR; TRYPSINOGEN; AMINOPHENOL DERIVATIVE; CFTR PROTEIN, HUMAN; N-(2,4-DI-TERT-BUTYL-5-HYDROXYPHENYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE; QUINOLONE DERIVATIVE;

ADULT; ALLELE; ARTICLE; BRONCHIECTASIS; CASE REPORT; CFTR GENE; CHANNEL GATING; CHLORIDE TRANSPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC CODE; GENOTYPE; HETEROZYGOSITY; HUMAN; IMMUNOREACTIVITY; IN VIVO STUDY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SINUSITIS; SPIROMETRY; SPUTUM CULTURE; TREATMENT OUTCOME; YOUNG ADULT; ADOLESCENT; AGONISTS; GENETICS; LUNG; MUTATION; PATHOPHYSIOLOGY; RADIOGRAPHY; THORAX RADIOGRAPHY;

ADOLESCENT; AMINOPHENOLS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; GENOTYPE; HUMANS; LUNG; MUTATION; QUINOLONES; RADIOGRAPHY, THORACIC; SPIROMETRY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84924860036     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-1198     Document Type: Article

References (17)

1. Goss CH, Ratjen F. Update in cystic fibrosis 2012. Am J Respir Crit Care Med. 2013;187(9):915-919.
2. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352(19):1992-2001.
3. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene:cloning and characterization of complementary DNA. Science. 1989;245(4922):1066-1073.
4. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010;363(21):1991-2003.
5. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009;106(44):18825-18830.
6. Ramsey BW, Davies J, McElvaney NG, et al; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-1672.
7. Flume PA, Liou TG, Borowitz DS, et al;for the VX 08-770-104 Study Group. Ivacaft or in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012;142(3):718-724.
8. Yu H, Burton B, Huang CJ, et al. Ivacaft or potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros. 2012;11(3):237-245.
9. Gilfillan A, Warner JP, Kirk JM, et al. P67L:a cystic fibrosis allele with mild effects found at high frequency in the Scottish population. J Med Genet. 1998;35(2):122-125.
10. McGarry ME, Nielson DW. Normalization of sweat chloride concentration and clinical improvement with ivacaft or in a patient with cystic fibrosis with mutation S549N. Chest. 2013;144(4):1376-1378.
11. Hoare S, McEvoy S, McCarthy CJ, et al. Ivacaft or imaging response in cystic fibrosis. Am J Respir Crit Care Med. 2014;189(4):484.
12. Van Goor F, Yu H, Burton B, Hoffman BJ. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2014;13(1):29-36.
13. Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013;45(10):1160-1167.
14. Rowe SM, Heltshe SL, Gonska T, et al GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Clinical mechanism of the cystic fibrosis transmem brane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med. 2014;190(2):175-184.
15. Sheppard DN, Rich DP, Ostedgaard LS, Gregory RJ, Smith AE, Welsh MJ. Mutations in CFTR associated with mild-disease-form Cl- channels with altered pore properties. Nature. 1993;362(6416):160-164.
16. Cholon DM, Quinney NL, Fulcher L, et al. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci Transl Med. 2014;6(246):246ra96.
17. Veit G, Avramescu RG, Perdomo D, et al. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci Transl Med. 2014;6(246):246ra97.